Warning letter
Bio-Medical Pharmaceutical Manufacturing Corporation: warning letter of Feb 5, 2026
FDA warning letter 719654 · Center for Drug Evaluation and Research (CDER)
Key facts
| Reference number | 719654 |
|---|---|
| Company | Bio-Medical Pharmaceutical Manufacturing Corporation |
| Subject | CGMP/Finished Pharmaceuticals/Adulterated |
| Issue date | Feb 5, 2026 |
| Posted date | Feb 10, 2026 |
| Issuing office | Center for Drug Evaluation and Research (CDER) |
| Product type | Drugs |
| CFR sections cited | 207, 207.41(a), 211.34, 211.63, 211.113(b), 211.165(a) |
| Inspection city | Houston |
| Inspection ZIP | 77053 |
| Inspection start date | Aug 25, 2025 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: